english english
Sažetak
Kratak sadržaj
Uvod: Cilj ove studije bio je određivanje antioksidativnog statusa pacijentima obolelim od multiple skleroze primenom standardnih biohemijskih testova tokom relapsa i remisije. Istovremeno, cilj studije je bio i odrediti uticaj pola, lekova koji modifikuju prirodan tok bolesti i kliničkih karakteristika multiple skleroze na analizirane antioksidanse.
Metode: Studija je obuhvatila 178 pacijenata sa relapsno-remitentnom multiplom sklerozom (61 u relapsu/ 117 u remisiji), 93 žena i 85 muškaraca, 40,9 ± 9,8 godina (prosečna starost 40,9 godina) i 80 zdravih kontrola, uparenih po godinama i polu. 132 pacijenata je primalo terapiju koja modifikuje prirodan tok bolesti. Određene su koncentracije mokraćne kiseline, ukupnog bilirubina, albumina i transferina u serumu pacijenata i kontrolne grupe. Proširena Skala Statusa Onesposobljenosti (EDSS), trajanje bolesti i broj relapsa po godini su predstavljali kliničke karakteristike multiple skleroze.
Rezultati: Antioksidativni status je niži kod obolelih od multiple skleroze u poređenju sa kontrolnom grupom. Nije utvrđena statistički značajna razlika u koncentracijama antioksidanasa tokom relapsa i remisije. Žene u odnosu na muškarce imaju slabiju antioksidativnu zaštita, koja se ogleda u nižim koncentracijama mokraćne kiseline, ukupnog bilirubina i albumina. Utvrđena je negativna korelacija između trajanja bolesti i vrednosti mokraćne kiseline i između broja relapsa po godini i koncentracije ukupnog bilirubina. Utvrđene su veće vrednosti albumina kod pacijenata koji su na terapiji koja modifikuje prirodan tok bolesti.
Zaključak:U ovoj studiji je dokazana upotreba standardnih biohemijskih analiza za procenu antioksidativne aktivnosti obolelih od multiple skleroze. Pol i kliničke karakteristike bolesti utiču na parametre antioksidativnog statusa i ukazuju na značaj personalizovane, komplementarne, pomoćne antioksidativne terapije u multiploj sklerozi.
Reference
1. Oh J, Vidal-Jordana A, Montalban X. Multiple Sclerosis: Clinical Aspects. Curr Opin Neurol. 2018;31(6):752-9.
2. Obradovic D, Andjelic T, Ninkovic M, Dejanovic B, Kotur-Stevuljevic J. Superoxide dismutase (SOD), advanced oxidation protein products (AOPP), and disease-modifying treatment are related to better relapse recovery after corticosteroid treatment in multiple sclerosis. Neurol Sci. 2021;42(8):3241-7.
3. Goodin DS, Reder AT, Bermel RA, Cutter GR, Fox RJ, John GR, et al. Relapses in multiple sclerosis: Relationship to disability. Mult Scler Relat Disord. 2016;6:10-20.
4. Ohl K, Tenbrock K, Kipp M. Oxidative stress in multiple sclerosis: Central and peripheral mode of action. Exp Neurol. 2016;277:58-67.
5. Singh A, Kukreti R, Saso L, Kukreti. S Oxidative Stress: A Key Modulator in Neurodegenerative Diseases. Molecules. 2019;24(8):1583.doi: 10.3390/molecules24081583.
6. Cobley JN, Fiorello ML, Bailey DM. 13 reasons why the brain is susceptible to oxidative stress. Redox Biol. 2018;15:490-503.
7. Ayala A, Munoz MF, Arguelles S. Lipid Peroxidation: Production, Metabolism, and Signaling Mechanisms of Malondialdehyde and 4-Hydroxy-2-Nonenal. Oxid Med Cell Longev. 2014:2014:360438.doi: 10.1155/2014/360438.
8. Siotto M, Filippi MM, Simonelli I, Landi D, Ghazaryan A, Vollaro S, et al. Oxidative Stress Related to Iron Metabolism in Relapsing Remitting Multiple Sclerosis Patients With Low Disability. Front Neurosci 2019;13:86. doi: 10.3389/fnins.2019.00086. eCollection 2019
9. Miller ED, Dziedzic A, Saluk-Bijak J, Bijak M. A Review of Various Antioxidant Compounds and their Potential Utility as Complementary Therapy in Multiple Sclerosis. Nutrients. 2019;11(7):1528. doi: 10.3390/nu11071528. PMID: 31284389; PMCID: PMC6682972.
10. Emamgholipour S, Hossein-Nezhad A, Sahraian MA, Askarisadr F, Ansari M. Evidence for Possible Role of Melatonin in Reducing Oxidative Stress in Multiple Sclerosis Through Its Effect on SIRT1 and Antioxidant Enzymes. Life Sci. 2016;145:34-41.
11. Miller E, Wachowicz B, Majsterek I. Advances in Antioxidative Therapy of Multiple Sclerosis. Curr Med Chem. 2013;20(37):4720-30.
12. Yang D, Su Z, Wu S, Bi Y, Li X, Li J, et al. Low antioxidant status of serum bilirubin, uric acid, albumin and creatinine in patients with myasthenia gravis. Int J Neurosci. 2016;126(12):1120-6.
13. Polman CH, Reingold SC, Banwell B, Clanet M, Cohen JA, Filippi M, et al. Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. Ann Neurol. 2011;69(2):292-302.
14. Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurol. 1983; 33(11): 1444-52.
15. Sautin YY, Johnson RJ. Uric acid: the oxidant-antioxidant paradox. Nucleosides Nucleotides Nucleic Acids. 2008;27(6):608-19.
16. Wang L, Hu W, Wang J, Qian W, Xiao H. Low serum uric acid levels in patients with multiple sclerosis and neuromyelitis optica: An updated meta-analysis. Mult Scler Relat Disord. 2016;9:17-22.
17. Niu PP, Song B, Wang X, Xu YM. Serum Uric Acid Level and Multiple Sclerosis: A Mendelian Randomization Study. Front Genet. 2020;11:254. doi: 10.3389/fgene.2020.00254.
18. Moccia M, Lanzillo R, Costabile T, Russo C, Carotenuto A, Sasso G, et al. Uric Acid in Relapsing-Remitting Multiple Sclerosis: A 2-year Longitudinal Study. J Neurol 2015;262(4):961-7.
19. Stocker R. Antioxidant activities of bile pigments. Antioxid Redox Signal. 2004;6(5):841-9.
20. Juping D, Yuan Y, Shiyong C, Jun L, Xiuxiu Z, Haijian Y, Jianfeng S, Bo S. Serum bilirubin and the risk of rheumatoid arthritis. J Clin Lab Anal. 2017;31(6):e22118. doi: 10.1002/jcla.22118.
21. Moos T, Nielsen TR, Skjorringe T, Morgan EH. Iron Trafficking Inside the Brain. J Neurochem. 2007;103(5):1730-40.
22. Dopsaj V, J Martinovic J, Dopsaj M, Stevuljevic JK, Bogavac-Stanojevic N. Gender-specific Oxidative Stress Parameters. Int J Sports Med. 2011;32(1):14-9.
23. Franco PG, Pasquini LA , Perez MJ, Rosato-Siri MV , Silvestroff L, Pasquini JM. Paving the Way for Adequate Myelination: The Contribution of galectin-3, Transferrin and Iron. FEBS Lett. 2015;589(22):3388-95
24. Aydin O, Ellidag HY, Eren E, Kurtulus F, Yaman A, Yılmaz N. Ischemia Modified Albumin Is an Indicator of Oxidative Stress in Multiple Sclerosis. Biochem Med. 2014;24(3):383-9.
25. Oliveira SR, Kallaur AP, Reiche EMV, Kaimen-Maciel DR, Panis C, Lozovoy MAB, et al Albumin and Protein Oxidation are Predictors that Differentiate Relapsing-Remitting from Progressive Clinical Forms of Multiple Sclerosis. Mol Neurobiol. 2017;54(4):2961-8.
26. Khalil M, Riedlbauer B, Langkammer C, Enzinger C, Ropele S, Stojakovic T,. Cerebrospinal fluid transferrin levels are reduced in patients with early multiple sclerosis. Mult Scler. 2014;20(12):1569-77.
27.Burger A, Kotze MJ, Stein DJ, van Rensburg SJ, Howells FM. The Relationship Between Measurement of in Vivo Brain Glutamate and Markers of Iron Metabolism: A Proton Magnetic Resonance Spectroscopy Study in Healthy Adults. Eur J Neurosci. 2020;51(4):984-990.
28.Anton FM, Garcia Puig J, Ramos T, Gonzalez P, Ordas J. Sex differences in uric acid metabolism in adults: evidence for a lack of influence of estradiol-17 beta (E2) on the renal handling of urate. Metabolism. 1986;35(4):343-8.
29. Naz F, Jyoti S, Rahul, Akhtar N, Siddique YH. Effect of Oral Contraceptive Pills on the Blood Serum Enzymes and DNA Damage in Lymphocytes Among Users. Indian J Clin Biochem. 2016;31(3):294-301.
30. Weaving G, Batstone GF, Jones RG. Age and sex variation in serum albumin concentration: an observational study. Ann Clin Biochem.2016;53(Pt 1):106-11.
31. Peng F, Deng X, Yu Y, Chen X, Shen L, Zhong X, et al. Serum Bilirubin Concentrations and Multiple Sclerosis. J Clin Neurosci. 2011;18(10):1355-9.
32. Kapitulnik J. Bilirubin: An Endogenous Product of Heme Degradation with Both Cytotoxic and Cytoprotective Properties. Mol Pharmacol. 2004;66(4):773-9.
33. Chen J , Tu Y, Connolly EC, Ronnett GV. Heme oxygenase-2 Protects Against Glutathione Depletion-Induced Neuronal Apoptosis Mediated by Bilirubin and Cyclic GMP. Curr Neurovasc Res. 2005;2(2):121-31.
34. Sotgiu S, Pugliatti M, Sanna A, Sotgiu A, Fois ML, Arru G, et al. Serum Uric Acid and Multiple Sclerosis. Neurol Sci. 2002;23(4):183-8.
35.Guerrero AL, Gutierrez F, Iglesias F, Martín-Polo J, Merino S, Martín-Serradilla JI, et al. Serum uric acid levels in multiple sclerosis patients inversely correlate with disability. Neurol Sci. 2011;32(2):347-50
36. Pakpoor J, Seminog OO, Ramagopalan SV, Goldacre MJ. Clinical associations between gout and multiple sclerosis, Parkinson’s disease and motor neuron disease: record-linkage studies. BMC Neurol. 2015;15:16. doi: 10.1186/s12883-015-0273-9.
37. Chittoor G, Kent JW Jr, Almeida M, Puppala S, Farook VS, Cole SA, et al. GWAS and transcriptional analysis prioritize ITPR1 and CNTN4 for a serum uric acid 3p26 QTL in Mexican Americans. BMC Genom. 2016;17:276.
38. Topic A, Vasic M, Markovic B, Milinkovic N, Dincic E. The Effects of Disease-Modifying Therapies on Oxidative Stress in Patients with Relapsing-Remitting Multiple Sclerosis. Clin Neuropharmacol. 2022;45(6):157-161.
39. Tobore TO. Oxidative/Nitroxidative Stress and Multiple Sclerosis. J Mol Neurosci. 2021;71(3):506-514. doi: 10.1007/s12031-020-01672-y.
Sva prava zadržana (c) 2025 Tamara Andjelić, Ivana Stevanović, Mirjana Mijušković, Bratislav Dejanović, Milica Ninković
Ovaj rad je pod Creative Commons Autorstvo 4.0 međunarodnom licencom.
The published articles will be distributed under the Creative Commons Attribution 4.0 International License (CC BY). It is allowed to copy and redistribute the material in any medium or format, and remix, transform, and build upon it for any purpose, even commercially, as long as appropriate credit is given to the original author(s), a link to the license is provided and it is indicated if changes were made. Users are required to provide full bibliographic description of the original publication (authors, article title, journal title, volume, issue, pages), as well as its DOI code. In electronic publishing, users are also required to link the content with both the original article published in Journal of Medical Biochemistry and the licence used.
Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.